Literature DB >> 12393498

Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.

David A Ingram1, Mary Jo Wenning, Kevin Shannon, D Wade Clapp.   

Abstract

The development of molecularly targeted treatments of adult leukemias warrants investigation of these targets in similar pediatric leukemias. The NF1 tumor suppressor gene, which encodes a GTPase activating protein for p21(ras), is frequently inactivated in juvenile myelomonocytic leukemia (JMML). Other patients with JMML acquire activating RAS gene mutations. Recipient mice reconstituted with Nf1-/- fetal hematopoietic cells develop a myeloproliferative disease (MPD) that models the human disease. JMML arises from clonal expansion of a hematopoietic stem cell, and JMML cells and murine Nf1-/- hematopoietic cells are hypersensitive to granulocyte macrophage-colony stimulating factor and KitL, the ligand for c-kit. We generated embryos doubly mutant for the Wv allele of c-kit and Nf1 to ask if reduction of c-kit activity would delay or prevent the development of MPD. Despite a reduction in c-kit activity to approximately 10% of wild-type levels, Nf1-/-;Wv/Wv cells induced MPD in recipient mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393498     DOI: 10.1182/blood-2002-08-2635

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.

Authors:  Jae-Lyun Lee; Jin Young Kim; Min-Hee Ryu; Hye Jin Kang; Heung Moon Chang; Tae-Won Kim; Hyoungnam Lee; Ji Hyun Park; Hee Cheol Kim; Jung Sun Kim; Yoon-Koo Kang
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

2.  Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.

Authors:  Laura S Haneline; Hilary White; Feng-Chun Yang; Shi Chen; Christie Orschell; Reuben Kapur; David A Ingram
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

3.  Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Authors:  Karl Staser; Su-Jung Park; Steven D Rhodes; Yi Zeng; Yong Zheng He; Matthew A Shew; Jeffrey R Gehlhausen; Donna Cerabona; Keshav Menon; Shi Chen; Zejin Sun; Jin Yuan; David A Ingram; Grzegorz Nalepa; Feng-Chun Yang; D Wade Clapp
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 4.  Magnetic resonance spectroscopy in common dementias.

Authors:  Kejal Kantarci
Journal:  Neuroimaging Clin N Am       Date:  2013-02-27       Impact factor: 2.264

5.  KRasG12D expression in the bone marrow vascular niche affects hematopoiesis with inflammatory signals.

Authors:  Cindy L Hochstetler; Yuxin Feng; Mehmet Sacma; Ashley K Davis; Mahil Rao; Chia-Yi Kuan; Li-Ru You; Hartmut Geiger; Yi Zheng
Journal:  Exp Hematol       Date:  2019-10-24       Impact factor: 3.084

6.  Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells.

Authors:  Kelly Hiatt; David A Ingram; Hannah Huddleston; Dan F Spandau; Reuben Kapur; D Wade Clapp
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

7.  MEK inhibition exerts temporal and myeloid cell-specific effects in the pathogenesis of neurofibromatosis type 1 arteriopathy.

Authors:  Rebekah Tritz; Farlyn Z Hudson; Valerie Harris; Pushpankur Ghoshal; Bhupesh Singla; Huiping Lin; Gabor Csanyi; Brian K Stansfield
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.